Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events.
Changhoon YooSeonggyu ByeonYeonghak BangJaekyung CheonJin W KimJee H KimHong J ChonBeodeul KangMyoung J KangIlhwan KimJun-Eul HwangJung H KangMyung A LeeJung Y HongHo Y LimBaek-Yeol RyooPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
The real-life clinical outcomes of regorafenib for patients who progressed on prior systemic therapy including ICIs were consistent with the phase III trial results. HFSR was significantly associated with better OS with regorafenib.